Adenoma, Pleomorphic
Welcome,         Profile    Billing    Logout  
 18 Companies   19 Products   19 Products   25 Mechanisms of Action   1 Trial   58 News 


12»
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment change, Trial completion date, Trial initiation date, Trial withdrawal, Trial primary completion date, Biopsy:  OCTSKIN: Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection (clinicaltrials.gov) -  Apr 4, 2019   
    P=N/A,  N=0, Withdrawn, 
    N=30 --> 0 | Trial completion date: Dec 2020 --> Dec 2017 | Initiation date: Jan 2019 --> Jun 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2020 --> Dec 2017
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date, Biopsy:  OCTSKIN: Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection (clinicaltrials.gov) -  Jul 18, 2018   
    P=N/A,  N=30, Not yet recruiting, 
    N=30 --> 0 | Trial completion date: Dec 2020 --> Dec 2017 | Initiation date: Jan 2019 --> Jun 2016 | Not yet recruiting --> Withdrawn | Trial primary completion date: Dec 2020 --> Dec 2017 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Trial initiation date, Trial primary completion date, Biopsy:  OCTSKIN: Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection (clinicaltrials.gov) -  Jan 18, 2017   
    P=N/A,  N=30, Not yet recruiting, 
    Trial primary completion date: Jun 2016 --> Sep 2017 Initiation date: Jul 2016 --> Mar 2017 | Trial primary completion date: Dec 2016 --> Dec 2017
  • ||||||||||  Enrollment change, Trial withdrawal, Trial primary completion date:  Quadrant Versus Superficial Parotidectomy (clinicaltrials.gov) -  Nov 8, 2016   
    P2/3,  N=0, Withdrawn, 
    Initiation date: Jul 2016 --> Mar 2017 | Trial primary completion date: Dec 2016 --> Dec 2017 N=116 --> 0 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2017 --> Jul 2016
  • ||||||||||  Vectibix (panitumumab) / Amgen
    Enrollment change, Trial primary completion date:  Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies (clinicaltrials.gov) -  Jan 11, 2016   
    P2,  N=0, Withdrawn, 
    Trial primary completion date: Feb 2016 --> Jun 2016 N=30 --> 0 | Trial primary completion date: Nov 2013 --> Aug 2011
  • ||||||||||  carboplatin / Generic mfg., paclitaxel / Generic mfg., dasatinib / Generic mfg.
    Enrollment closed, Metastases:  Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer (clinicaltrials.gov) -  Jul 14, 2015   
    P=N/A,  N=15, Active, not recruiting, 
    Trial primary completion date: Aug 2015 --> Dec 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Dec 2015 | Recruiting --> Active, not recruiting
  • ||||||||||  Avastin (bevacizumab) / Roche
    Trial primary completion date:  Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer (clinicaltrials.gov) -  Jun 11, 2015   
    P2,  N=22, Active, not recruiting, 
    Completed --> Terminated; Early closure based on audit by study investigators after 3 patients died on study. Trial primary completion date: Jul 2015 --> May 2016
  • ||||||||||  Trial primary completion date:  Quadrant Versus Superficial Parotidectomy (clinicaltrials.gov) -  Jun 27, 2014   
    P2/3,  N=116, Recruiting, 
    Recruiting --> Suspended Trial primary completion date: Sep 2015 --> Jul 2017
  • ||||||||||  Trial initiation date:  Quadrant Versus Superficial Parotidectomy (clinicaltrials.gov) -  Jun 27, 2014   
    P2/3,  N=116, Recruiting, 
    Trial primary completion date: Sep 2015 --> Jul 2017 Initiation date: Sep 2012 --> Jun 2014
  • ||||||||||  Enrollment open, Trial initiation date, Trial primary completion date:  Quadrant Versus Superficial Parotidectomy (clinicaltrials.gov) -  Jun 27, 2014   
    P2/3,  N=116, Recruiting, 
    Initiation date: Sep 2012 --> Jun 2014 Not yet recruiting --> Recruiting | Initiation date: Sep 2012 --> Jun 2014 | Trial primary completion date: Sep 2015 --> Jul 2017
  • ||||||||||  sorafenib / Generic mfg.
    Enrollment change:  Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer (clinicaltrials.gov) -  May 29, 2014   
    P2,  N=56, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Sep 2012 --> Jun 2014 | Trial primary completion date: Sep 2015 --> Jul 2017 N=74 --> 56